MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

BioMarin Pharmaceutical Inc

Geschlossen

BrancheGesundheitswesen

67.41 -1.43

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

66.74

Max

68.31

Schlüsselkennzahlen

By Trading Economics

Einkommen

19M

125M

Verkäufe

1.6M

747M

KGV

Branchendurchschnitt

31.986

63.778

EPS

0.92

Gewinnspanne

16.719

Angestellte

3,040

EBITDA

39M

195M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+45.48% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

23. Apr. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.6B

14B

Vorheriger Eröffnungskurs

68.84

Vorheriger Schlusskurs

67.41

Nachrichtenstimmung

By Acuity

43%

57%

139 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Juni 2024, 17:41 UTC

Wichtige Markttreiber

Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion

21. Aug. 2024, 11:30 UTC

Top News

S&P 500 Futures Up In Premarket Trading; Target, Keysight Technologies Lead

Peer-Vergleich

Kursveränderung

BioMarin Pharmaceutical Inc Prognose

Kursziel

By TipRanks

45.48% Vorteil

12-Monats-Prognose

Durchschnitt 99.39 USD  45.48%

Hoch 127 USD

Tief 70 USD

Basierend auf 24 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für BioMarin Pharmaceutical Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

24 ratings

19

Buy

5

Halten

0

Sell

Technischer Score

By Trading Central

67.835 / 71.32Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

139 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.